低剖面双金属层镍钛微网支架与单层颈动脉支架的当代结果对比
单中心回顾性非随机研究纳入200例患者共205例择期颈动脉支架术,比较Roadsaver/Casper双金属层微网支架与第一代支架的围术期及中期结果。Roadsaver组手术时间更短且桡动脉入路更常见,30天卒中/TIA/死亡率和1年、3年原发通畅率与第一代支架组无显著差异。
要点
- Roadsaver/Casper支架组平均手术时间40.7±16.9分钟,短于第一代支架组的49.4±27.3分钟。
- Roadsaver组桡动脉入路使用率24%,高于第一代支架组的5%。
- 两组30天卒中/TIA/死亡率和中期原发通畅率无显著差异。
核心结论
- Roadsaver/Casper低剖面双金属层微网支架在30天和随访期事件率低,与其他支架相似。
研究设计与样本
- 单中心、回顾性、非随机研究,纳入200例患者共205例择期颈动脉支架术,比较Roadsaver/Casper支架(100例手术,97例患者)与第一代颈动脉支架(90例手术,88例患者),15例CGuard支架单独报告。
主要发现
- Roadsaver/Casper组平均手术时间40.7±16.9分钟 vs 第一代支架组49.4±27.3分钟(p=0.008)。
- Roadsaver/Casper组桡动脉穿刺入路更常见(24% vs 5%;p<0.001)。
- 30天卒中/TIA/死亡率Roadsaver组3% vs 第一代支架组1%(p=0.623)。
- 1年和3年原发通畅率Roadsaver/Casper组分别为100%和93.4%,其他支架组分别为99%和94.3%(p=0.95)。
关键数值与推荐
- 主要终点为重大不良脑血管事件(MACE),包括死亡、同侧卒中和短暂性脑缺血发作(TIA)。
- 次要终点包括支架内狭窄率、再干预需求以及不良心血管事件(心肌梗死、心律失常、需正性肌力药物支持)。
临床怎么用
- Roadsaver/Casper支架可用于治疗症状性和易损颈动脉斑块,围术期和中期结果与其他支架相似。
- 该支架手术时间更短且更常经桡动脉入路,可能简化操作流程。
局限性
- 单中心回顾性非随机设计,可能存在选择偏倚。
- 样本量有限,事件率低,统计效能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate patients characteristics, procedural details, perioperative outcomes, and midterm results of carotid artery stenting (CAS) performed with the Roadsaver/Casper stent (Terumo Corp, Tokyo, Japan) as compared to concurrent patients treated with other commercially available carotid stents. MATERIALS AND METHODS: This is a single-center, retrospective, nonrandomized study including 200 consecutive patients who underwent a total of 205 elective CAS procedures due to severe internal carotid artery stenosis between April 2015 and December 2018. Procedural data and outcomes for patients treated with the Roadsaver/Casper stent implantation (100 procedures, in 97 patients) vs first-generation carotid stents implantations (90 procedures, in 88 patients) were compared. Fifteen patients were treated with CGuard carotid stent (InspireMD, Tel Aviv, Israel), and outcomes were reported separately. Primary endpoints were the occurrence of major adverse cerebrovascular events (MACE), including death, ipsilateral stroke, and transitory ischemic attack (TIA). Secondary endpoints were the rate of intrastent stenosis, the need for reintervention, and the occurrence of adverse cardiovascular events, including myocardial infarction, arrhythmias, and need for inotropic support. RESULTS: No difference in demographics and preoperative risk factors were observed between patients treated with and without the Roadsaver/Casper stent. The mean procedure time was shorter in the Roadsaver/Casper group (40.7±16.9 vs 49.4±27.3 minutes; p=0.008), while radial percutaneous access was more frequent (24% vs 5%; p<0.001). The rate of stroke/TIA/death at 30 days was 3% in the Roadsaver group vs 1% in the first-generation stent group (p=0.623). The primary patencyrate was 100% and 93.4% at 1- and 3-year of follow-up in the Roadsaver/Casper groupand 99% and 94.3% in the other stent group, respectively (p=0.95). CONCLUSIONS: In this real-world cohort of patients undergoing CAS, the Roadsaver/Casper stent was used to treat more symptomatic and vulnerable carotid plaques as compared to other carotid stents. Nevertheless, patients treated with this low-profile dual-layer micromesh stent showed low events rates at both 30 days and follow-up, similar to that observed for other stents.
引用
- Kahlberg A, Bilman V, Ardita V, et al. Contemporary Results of Carotid Artery Stenting Using Low-Profile Dual-Metal Layer Nitinol Micromesh Stents in Relation to Single-Layer Carotid Stents. J Endovasc Ther. 2021. PMID: 34137659. doi:10.1177/15266028211025046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。